Entities / Company
Merck KGaA.
German multinational science and technology company
- Reports this week
- 4
- Active events
- 3
- Connections
- 656
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
-
Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.Some support1 report
-
Merck KGaA and ABVC BioPharma are competing for investment as healthcare companies.Some support1 report
-
Morgan Stanley reduced its price target on Merck KGaA while Manufacturers Life Insurance Company increased its holdings in the stock.Some support1 report
Earlier this month
-
Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.Well supported3 reports1 development inside
-
MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Some support1 report
-
Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Some support5 reports
-
A combination drug from Merck KGaA and Inhibrx Biosciences showed a higher response rate, leading to a stock price drop reported by Reuters.Some support1 report
-
Merck KGaA announced a definitive agreement to acquire Bio-Techne.Well supported6 reports
-
Merck KGaA is the subject of analyst rating upgrades from HSBC and Scotiabank, alongside increased stock holdings by Geode Capital Management and related SEC filings.Some support1 report
-
Merck KGaA won an award for sustainable innovation.Some support1 report
One to three months ago
-
Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.Some support2 reports1 development inside
-
Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.Some support3 reports
-
Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.Some support1 report
-
Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.Some support1 report
-
Multiple financial institutions, including Norges Bank, Morgan Stanley, and Geode Capital Management, adjusted their holdings in Merck KGaA shares.Some support3 reports
-
Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.Well supported18 reports10 developments inside
-
Merck KGaA's headquarters are located in Darmstadt, Germany.Some support1 report1 development inside
-
Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.Some support1 report
-
Merck KGaA operates as a science and technology company in Germany.Well supported13 reports1 development inside
-
Norges Bank acquired a new stake in Merck KGaA worth $3.9 billion, filing the required Form 13F with the SEC.Some support4 reports1 development inside
-
Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.Some support1 report
-
MarketBeat is reporting on the company performance of Merck KGaA, a science company based in Germany.Some support1 report
-
Aspen Pharmacare gained rights to manufacture medicines with Merck/MSD to improve access to pharmaceuticals in Africa.Some support2 reports2 developments inside
-
Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.Some support2 reports2 developments inside
-
Pfizer and Merck KGaA are navigating market pressures as the COVID franchise revenue streams decline.Some support1 report
-
Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.Some support1 report
-
A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.Some support1 report1 development inside
-
Merck KGaA filed required documentation with the Securities and Exchange Commission regarding public company oversight.Well supported9 reports1 development inside
-
Morgan Stanley boosted its position in Merck KGaA, while Geode Capital Management lifted its holdings in the company.Some support1 report
-
Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.Some support1 report
-
Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.Some support1 report
-
An analyst report was released on July 4, 2026, leading to a target price increase for Merck KGaA.Some support6 reports
-
Merck KGaA and Eli Lilly and Company experienced stock declines on July 20, 2026, amid market sentiment shifts.Some support1 report
Gone quiet
No new reports in 90+ days-
Merck KGaA and Physiomics plc are providing modeling and data science services.Some support1 report
-
Institutional investors, including Sumitomo Mitsui Trust Holdings, Inc., decreased their holdings in Merck KGaA by 10.1% in Q1 2026.Some support1 report
-
Multiple financial firms, including Citigroup, Bank of America, and Cantor Fitzgerald, issued rating updates on Merck KGaA shares.Some support8 reports
-
Glocer has been appointed to the board of directors at both Merck KGaA and Morgan Stanley.Some support2 reports
-
Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms.Some support1 report1 development inside
-
Jefferies Financial Group started coverage on Merck KGaA shares.Some support1 report
-
Roy Vagelos, co-founder of Regeneron, has joined Merck KGaA, rising from R&D to COO.Some support1 report
-
Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.Some support1 report
-
Merck KGaA announced a new CEO who previously gained experience at the company.Some support1 report
-
Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.Some support1 report
-
Morgan Stanley bought shares of Merck KGaA on June 16, 2026.Some support1 report
-
Keytruda received FDA approval for cancer treatment, involving Merck KGaA.Some support3 reports
-
Merck KGaA has acquired Terns Pharmaceuticals in a deal valued at $6.7 billion.Some support1 report
-
Geode Capital Management increased its stake in Merck KGaA by 0.4%, purchasing a new stake valued at approximately $3.99 billion.Some support2 reports
-
Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.Some support1 report
-
The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.Speculative2 reports
-
Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.Some support3 reports
-
Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.Some support1 report
-
Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.Some support1 report
-
Merck & Co.'s board of directors declared financial actions regarding shareholder returns on May 26, 2026.Some support1 report
-
Merck & Co. is based in Rahway, N.J., USA.Some support1 report
-
Merck & Co. and Hengrui Pharma outperformed the S&P 500 in recent stock returns and paid upfront license agreement charges on August 28, 2025.Some support1 report
-
IO Biotech compared its vaccine to Merck & Co.'s Keytruda.Some support1 report
-
Merck & Co. and Avista are appealing to income-focused investors.Some support1 report
-
Merck & Co., GEA Group, and DeLaval are driving global innovations across biopharma, process technology, and dairy farming.Some support1 report
-
Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.Some support1 report
-
The market is currently dominated by key players, including Merck & Co., Amgen, and Moderna.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Merck KGaA this week
News at the entities that move Merck KGaA most-
Norges Bank TransactionalNorges Bank acquired a new position in Manulife Financial.Moves Merck KGaA
-
FDA OperationalFDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.Moves Merck KGaA
-
Royal Bank of Canada TransactionalRoyal Bank of Canada reiterated its rating on VAT Group AG, while Jefferies Financial Group upgraded the rating on the Switzerland-based company.Moves Merck KGaA
-
Moderna OperationalModerna and BioNTech are recognized as leaders in the personalized cancer vaccine space.Moves Merck KGaA
-
Eli Lilly and Company OperationalEli Lilly and Company acquired Point and established a supply agreement with EUZ.Moves Merck KGaA
-
Securities and Exchange Commission StructuralSECP is investigating the role of PSX as a frontline regulator.Moves Merck KGaA
Connections
The 40 strongest of 656, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
E. Merck Structural
Merck KGaA's related entity was established as a subsidiary of E. Merck.
-
MSD Structural
MSD is a subsidiary of Merck & Co., Inc., with the name varying based on geographic market.
-
Bio-Techne Transactional
Merck KGaA is acquiring Bio-Techne through a definitive shareholder sale agreement.
-
Moderna Operational
Merck KGaA and Moderna maintain a strategic partnership focused on jointly developing and testing personalized mRNA cancer vaccines.
-
Dean Y. Li Structural
Dean Y. Li serves in an executive capacity at Merck Research Laboratories.
-
Norges Bank Transactional
Norges Bank acquired a new stake in Merck KGaA valued at approximately $3.9 billion.
-
FDA Operational
The FDA evaluates and approves pharmaceutical products submitted by Merck KGaA, granting market access based on rigorous review processes.
-
Securities and Exchange Commission Structural
Merck KGaA operates under the formal regulatory oversight of the SEC, specifically regarding mandatory institutional holdings reports (Form 13F).
Show all 40 connections
-
Morgan Stanley Structural
The relationship is structural, maintained through shared board representation and continuous active investment and rating coverage by Morgan Stanley.
-
Eli Lilly and Company Operational
The two pharmaceutical companies are direct competitors in the advanced drug development market.
-
Merck Animal Health Structural
Merck Animal Health operates as a dedicated division of the larger entity, Merck KGaA.
-
SEC Structural
Merck KGaA is subject to mandatory institutional holdings and investment activity disclosure requirements enforced by the SEC.
-
Pfizer Operational
The companies actively compete in various therapeutic markets, collaborate on specific product approvals, and have engaged in corporate transactions.
-
Royal Bank of Canada Transactional
RBC provides financial ratings and research notes on Merck KGaA stock, including increases and downgrades.
-
China Structural
Merck KGaA conducts business operations, including product sourcing and sales, within the Chinese market.
-
Ligand Pharmaceuticals Operational
Ligand Pharmaceuticals and Merck KGaA maintain ongoing partnerships and alliances for drug development.
-
Veeva Systems Structural
Veeva provides specialized Agentic CRM and AI tools essential for Merck KGaA's ongoing operational functions.
-
Belén Garijo Structural
Belén Garijo holds the position of CEO at Merck KGaA.
-
Kenneth Frazier Transactional
A served as the leader of B, a role held until 2021.
-
HSBC Mentioned together
HSBC provides financial research reports and target price analysis on Merck KGaA stock.
-
Oncolytics Biotech Operational
Oncolytics Biotech and Merck KGaA are engaged in a co-development agreement for the drug pelareorep.
-
Bank of America Mentioned together
Bank of America provides financial analysis, raising price targets and issuing buy ratings for Merck KGaA.
-
Gilead Sciences Operational
The two companies are current competitors in the fragmented HIV drug market and share a history of collaboration.
-
Leerink partners Mentioned together
Leerink partners provides financial coverage, consistently raising price targets and ratings for Merck KGaA.
-
AstraZeneca Operational
The two companies actively compete against each other within the global pharmaceutical market.
-
Daiwa Securities Operational
The relationship is characterized by market coverage and analyst influence, where upgrades impact market sentiment.
-
Danaher Corporation Operational
The two companies are active competitors operating within the diagnostic market space.
-
Hilltop Holdings Inc. Transactional
Merck KGaA reduced its investment stake in Hilltop Holdings Inc. by 18.5% during Q1.
-
Bioinvent Operational
Both companies are actively competing in the development of novel anti-TNFR2 antibodies.
-
Geode Capital Management Transactional
Geode Capital Management is divesting its stake in Merck KGaA following an initial increase during the fourth quarter of 2026.
-
Severino Structural
Severino held a past executive position within Merck KGaA.
-
Scotiabank Mentioned together
Scotiabank provides financial analysis and price target updates regarding Merck KGaA stock.
-
AbbVie Operational
AbbVie and Merck KGaA are active competitors in the pharmaceutical development and sales market.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides financial ratings and price targets for Merck KGaA in research notes.
-
Manufacturers Life Insurance Company Transactional
Manufacturers Life Insurance Company increased its investment holdings in Merck KGaA stock.
-
Europe Shared context
Merck KGaA operates, serves customers, and seeks to bring benefits to the market within the geographical and regulatory context of Europe.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides analyst coverage and ratings for Merck KGaA shares.
-
Citigroup Mentioned together
The relationship is based on co-mention in financial media, specifically through shared analyst coverage and ratings.
-
Wells Fargo Mentioned together
Wells Fargo analysts provided price target updates regarding Merck KGaA stock.
-
MarketBeat Mentioned together
MarketBeat tracks, aggregates, and reports on the financial performance and stock status of Merck KGaA.
History
Events by the month they beganOctober 2026
3 events- Nasdaq added Moderna to its Nasdaq-100 index, and Moderna combined its vaccine with Merck's drug.
- Merck KGaA and ABVC BioPharma are competing for investment as healthcare companies.
- Morgan Stanley reduced its price target on Merck KGaA while Manufacturers Life Insurance Company increased its holdings in the stock.
September 2026
9 events- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.
- A combination drug from Merck KGaA and Inhibrx Biosciences showed a higher response rate, leading to a stock price drop reported by Reuters.
- Merck KGaA is the subject of analyst rating upgrades from HSBC and Scotiabank, alongside increased stock holdings by Geode Capital Management and related SEC filings.
- Merck KGaA won an award for sustainable innovation.
- Moderna and Merck KGaA are working on personalized melanoma shots, with manufacturing challenges being discussed by Amy Walker.
- Moderna and Novavax partnered with Merck KGaA on an individualized neoantigen program, driven by positive Phase 2b melanoma data.
- Merck KGaA and AstraZeneca's drug pipelines are facing market competition, with J.P. Morgan reiterating an Overweight rating.
- Robert Plenge holds various appointments, including Chief Research Officer at Bristol-Myers Squibb, and serves on the boards of BioMarin Pharmaceutical and the PhRMA Foundation.
- Pfizer, BioNTech, Merck KGaA, and Moderna announced joint developments regarding Comirnaty and a new cancer treatment.
August 2026
7 events- Multiple financial institutions, including Norges Bank, Morgan Stanley, and Geode Capital Management, adjusted their holdings in Merck KGaA shares.
- Merck KGaA's headquarters are located in Darmstadt, Germany.
- Norges Bank acquired a new stake in Merck KGaA worth $3.9 billion, filing the required Form 13F with the SEC.
- Merck KGaA stock saw activity as an EVP sold shares, while Mirae Asset increased its stake, alongside Norges Bank's previous acquisition.
- MarketBeat is reporting on the company performance of Merck KGaA, a science company based in Germany.
- Pfizer and Merck KGaA are navigating market pressures as the COVID franchise revenue streams decline.
- Merck KGaA, Gilead Sciences, and Pfizer are competing in the fragmented HIV drug market.
Show 2 earlier months
July 2026
10 events- Aspen Pharmacare gained rights to manufacture medicines with Merck/MSD to improve access to pharmaceuticals in Africa.
- A critical strategic collaboration has formed involving Hoffmann-La Roche, Recursion, Recordati, Moderna, Sanofi, and Merck KGaA to diversify pipelines through automated biological research.
- Morgan Stanley boosted its position in Merck KGaA, while Geode Capital Management lifted its holdings in the company.
- Merck KGaA received a reaffirmed neutral rating, reduced its stake by 18.5%, and filed 13F reports with the SEC.
- Litigation in Europe and ongoing FDA review are impacting the market viability and stock performance of Merck KGaA and SamChunDang Pharm.
- An analyst report was released on July 4, 2026, leading to a target price increase for Merck KGaA.
- Merck KGaA and Eli Lilly and Company experienced stock declines on July 20, 2026, amid market sentiment shifts.
- Merck KGaA and Physiomics plc are providing modeling and data science services.
- Institutional investors, including Sumitomo Mitsui Trust Holdings, Inc., decreased their holdings in Merck KGaA by 10.1% in Q1 2026.
- Multiple financial firms, including Citigroup, Bank of America, and Cantor Fitzgerald, issued rating updates on Merck KGaA shares.
June 2026
31 events- Major pharmaceutical companies face industry-wide pressure from patent cliffs and the need to streamline operations.
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.
- Merck KGaA announced a definitive agreement to acquire Bio-Techne.
- Moderna announced a collaboration with Merck KGaA regarding a personalized cancer vaccine platform.
- Merck KGaA operates as a science and technology company in Germany.
- Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.
- Merck KGaA filed required documentation with the Securities and Exchange Commission regarding public company oversight.
- Glocer has been appointed to the board of directors at both Merck KGaA and Morgan Stanley.
- Merck KGaA received analyst coverage and increased institutional stake in its stock from various firms.
- Jefferies Financial Group started coverage on Merck KGaA shares.
- Roy Vagelos, co-founder of Regeneron, has joined Merck KGaA, rising from R&D to COO.
- Merck KGaA agreed to acquire Bio-Techne, while an analyst boosted the price target for Avantor stock.
- Merck KGaA announced a new CEO who previously gained experience at the company.
- Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.
- Morgan Stanley bought shares of Merck KGaA on June 16, 2026.
- Keytruda received FDA approval for cancer treatment, involving Merck KGaA.
- Merck KGaA has acquired Terns Pharmaceuticals in a deal valued at $6.7 billion.
- Geode Capital Management increased its stake in Merck KGaA by 0.4%, purchasing a new stake valued at approximately $3.99 billion.
- Evaxion will present clinical trial data at the ESMO Congress 2025 in Berlin, utilizing therapy from Merck Sharp & Dohme.
- The FDA is currently evaluating data needed for alternate dosing licenses, while sales in China declined significantly in 2025.
- Merck, Eli Lilly, Biogen, and Eisai are all competing in the development of drugs for Alzheimer's disease.
- Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.
- Hengrui has formed broad partnerships and licensing deals with Merck & Co., GSK, and Merck KGaA regarding advanced heart disease drugs for hypertrophic cardiomyopathy.
- Merck & Co.'s board of directors declared financial actions regarding shareholder returns on May 26, 2026.
- Merck & Co. is based in Rahway, N.J., USA.
- Merck & Co. and Hengrui Pharma outperformed the S&P 500 in recent stock returns and paid upfront license agreement charges on August 28, 2025.
- IO Biotech compared its vaccine to Merck & Co.'s Keytruda.
- Merck & Co. and Avista are appealing to income-focused investors.
- Merck & Co., GEA Group, and DeLaval are driving global innovations across biopharma, process technology, and dairy farming.
- Immutep and Merck are combining their therapies, with presentations made at WCLC in Barcelona and engagements held in Paris and Chicago.
- The market is currently dominated by key players, including Merck & Co., Amgen, and Moderna.